Related Experiment Videos
Risperidone and paroxetine given singly and in combination for bipolar depression
Richard C Shelton1, Stephen M Stahl
1Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA. richard.Shelton@vanderbilt.edu
The Journal of Clinical Psychiatry
|January 12, 2005
Summary
Risperidone and paroxetine, alone or combined, showed modest, equal effectiveness for bipolar depression when added to mood stabilizers. The treatments had a low rate of switching to mania or hypomania.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Bipolar depression is a significant clinical challenge with limited research.
- Current treatments often have limited efficacy or side effects.
Purpose of the Study:
- To evaluate the efficacy of risperidone, paroxetine, and their combination in treating bipolar depression.
- To assess the safety and tolerability of these treatment strategies.
Main Methods:
- A 12-week, double-blind, randomized study involving 30 patients with bipolar disorder (depressed phase).
- Patients received a mood stabilizer plus risperidone, paroxetine, or the combination.
- Data collected between August 1999 and September 2001.
Main Results:
- All treatment groups showed significant reductions in depression ratings from baseline.
- No significant differences in overall treatment outcomes were observed between the groups.
- The rate of switching to mania or hypomania was low across all groups.
Conclusions:
- Risperidone, paroxetine, and their combination are similarly effective, albeit modestly, as add-on treatments for bipolar depression.
- Potential drug-drug interactions may have influenced paroxetine dosage.
- Further research with different selective serotonin reuptake inhibitors (SSRIs) in combination therapy is warranted.